These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 27039138)

  • 1. PCSK9 Inhibitors for Statin Intolerance?
    Waters DD; Hsue PY; Bangalore S
    JAMA; 2016 Apr; 315(15):1571-2. PubMed ID: 27039138
    [No Abstract]   [Full Text] [Related]  

  • 2. Alternatives to statins in intolerant patients do lower cholesterol, study finds.
    Torjesen I
    BMJ; 2016 Apr; 353():i1926. PubMed ID: 27048348
    [No Abstract]   [Full Text] [Related]  

  • 3. Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial.
    Nissen SE; Stroes E; Dent-Acosta RE; Rosenson RS; Lehman SJ; Sattar N; Preiss D; Bruckert E; Ceška R; Lepor N; Ballantyne CM; Gouni-Berthold I; Elliott M; Brennan DM; Wasserman SM; Somaratne R; Scott R; Stein EA;
    JAMA; 2016 Apr; 315(15):1580-90. PubMed ID: 27039291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Profile of Statin Intolerance in the Phase 3 GAUSS-2 Study.
    Cho L; Rocco M; Colquhoun D; Sullivan D; Rosenson RS; Dent R; Xue A; Scott R; Wasserman SM; Stroes E
    Cardiovasc Drugs Ther; 2016 Jun; 30(3):297-304. PubMed ID: 26936841
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial.
    Sullivan D; Olsson AG; Scott R; Kim JB; Xue A; Gebski V; Wasserman SM; Stein EA
    JAMA; 2012 Dec; 308(23):2497-506. PubMed ID: 23128163
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of Ezetimibe Alone or in Addition to a Statin on Plasma PCSK9 Concentrations in Patients with Type 2 Diabetes and Hypercholesterolemia: A Pilot Study.
    Miyoshi T; Nakamura K; Doi M; Ito H
    Am J Cardiovasc Drugs; 2015 Jun; 15(3):213-9. PubMed ID: 25896669
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Newer cholesterol-lowering agents: What you must know.
    Firnhaber JM
    J Fam Pract; 2018 Jun; 67(6):339;341;344;345. PubMed ID: 29879234
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Updates on prevention: obesity, ezetimibe, PCSK9, and HIV infection.
    Lüscher TF
    Eur Heart J; 2016 Dec; 37(48):3545-3548. PubMed ID: 28087743
    [No Abstract]   [Full Text] [Related]  

  • 9. Evolocumab (AMG 145) for primary hypercholesterolemia.
    Langslet G; Emery M; Wasserman SM
    Expert Rev Cardiovasc Ther; 2015 May; 13(5):477-88. PubMed ID: 25824308
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PCSK9 inhibitors: monoclonal antibodies for the treatment of hypercholesterolemia.
    Paton DM
    Drugs Today (Barc); 2016 Mar; 52(3):183-92. PubMed ID: 27186592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and the Future of Lipid Lowering Therapy.
    Joseph L; Robinson JG
    Prog Cardiovasc Dis; 2015; 58(1):19-31. PubMed ID: 25936907
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PCSK9 inhibition: the next statin?
    Vogel RA
    J Am Coll Cardiol; 2012 Jun; 59(25):2354-5. PubMed ID: 22465426
    [No Abstract]   [Full Text] [Related]  

  • 13. A study in high-risk, maximally pretreated patients to determine the potential use of PCSK9 inhibitors at various thresholds of total and LDL cholesterol levels.
    Groves C; Shetty C; Strange RC; Waldron J; Ramachandran S
    Postgrad Med J; 2017 Apr; 93(1098):205-208. PubMed ID: 27531965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PCSK9 Inhibitors and Cardiovascular Events.
    Goemann IM; Londero TM; Dora JM
    N Engl J Med; 2015 Aug; 373(8):773-4. PubMed ID: 26287856
    [No Abstract]   [Full Text] [Related]  

  • 15. PCSK9 Inhibitors and Cardiovascular Events.
    Sabatine MS; Wasserman SM; Stein EA
    N Engl J Med; 2015 Aug; 373(8):774-5. PubMed ID: 26295078
    [No Abstract]   [Full Text] [Related]  

  • 16. PCSK9 Inhibitors and Cardiovascular Events.
    Auer J; Berent R; Primus C
    N Engl J Med; 2015 Aug; 373(8):773. PubMed ID: 26287855
    [No Abstract]   [Full Text] [Related]  

  • 17. PCSK9 Inhibitors and Cardiovascular Events.
    Robinson JG; Kastelein JJ
    N Engl J Med; 2015 Aug; 373(8):774. PubMed ID: 26287854
    [No Abstract]   [Full Text] [Related]  

  • 18. PCSK9 inhibitors reduce cardiovascular events, preliminary data show.
    Mayor S
    BMJ; 2015 Mar; 350():h1508. PubMed ID: 25782694
    [No Abstract]   [Full Text] [Related]  

  • 19. Alirocumab for the treatment of hyperlipidemia in high-risk patients: an updated review.
    Farnier M
    Expert Rev Cardiovasc Ther; 2017 Dec; 15(12):923-932. PubMed ID: 29171769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of Hypercholesterolemia With PCSK9 Inhibitors in Heart Transplant Recipients. First Experience in Spain.
    Groba-Marco MDV; Del Castillo-García S; Barge-Caballero G; Barge-Caballero E; Couto-Mallón D; Crespo-Leiro MG
    Rev Esp Cardiol (Engl Ed); 2019 Dec; 72(12):1084-1086. PubMed ID: 31474577
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.